{"name":"Galimedix Therapeutics Inc","slug":"galimedix-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxQQmxNTjllUlVXSUxmb09Id3dDaENoY0F6a2lPTEtnNXdkTlJjR2oxbWloeFZXWTJXUHNrdnhIMTJKOEdSbHRrWXNnRndvUnVVZ1hRNlFKeHhvbVh1dTNGV1Jtd2RIWkpINE02ZlRUQTZaaklrRDBBcElNN0NTeDFsLV9Lb3o1Q29Ob2xrWTNzcW8?oc=5","date":"2026-04-01","type":"pipeline","source":"pharmaphorum","summary":"LSX2026: On a therapeutic vision for ocular disease, with Alexander Gebauer - pharmaphorum","headline":"LSX2026: On a therapeutic vision for ocular disease, with Alexander Gebauer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwJBVV95cUxNaE1WMXFuUWg1Z1NDaUVBeTR4WkswSDJmbmVjTS1zQjBJLXNhakN5U2NrdFROTUpYemRyZHpwMXViLUV1VElkYWR0N29FX1JZREVETW9BZmRaa0hoU0ZaQUE1eVV2TTlKNDdtN3RXREVRTzlRVzZESG02V0U2WExBb1hxYkI3WnFlLUV1MlBsY0hERmlaR0VsRDlxaFhfeklVMVhCbUJyR0pxa1JNS3ljR1V4WDFKQ1lmZ1hxaERGMFZCUXBnUk8yc1dDLUVqblJwSDRMWHZCNlBqVTFqYTJmVm1nTzdYNzZVM2o2Z2lDcWF6X3VoUUxRNHZNc0FBTENDRWRRZ2J1WExUbV9oQW1aWDZIblBiV20zcDU1YlF3UQ?oc=5","date":"2026-03-20","type":"pipeline","source":"GlobeNewswire","summary":"Galimedix Therapeutics presents strong pharmacokinetic - GlobeNewswire","headline":"Galimedix Therapeutics presents strong pharmacokinetic","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigJBVV95cUxNd0o0RzZNX2ttRGstUEtUZ19iMkVCY1lvVnd3elo4RXVzc2FNdm5td09zMnhNSC03SzFGb2QtQmlUbE1JWllyVlNqQUpaWlVES0lwem51SC1Nak1odXlVYS1NMkN6NkZfUFVxVXAyTVBKT3RLYy16X2doRU5zUklicEtRdzllanFrdk5qYVYwRzJYM2xCVjU0bjEyV2V6RlhKOGhwU2lxNU5pdXJ4OC1UWE9Ha3dkc3Z2TzJrbVNTSDQ1SXNtRHdZSkNMYjJhN0RheTJGNVNhRFJnWHZPYTk4U21LdmZORmVFYmhOTTdtTnM2WEdVZ0hXZXlNQ2o1Zi1kYWZXVndwbVBoZw?oc=5","date":"2026-03-12","type":"deal","source":"GlobeNewswire","summary":"Galimedix Therapeutics earns milestone payment in ophthalmology partnership with Théa Open Innovation - GlobeNewswire","headline":"Galimedix Therapeutics earns milestone payment in ophthalmology partnership with Théa Open Innovation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxOcjBGclBhdE5xNnBBcU40bWZvVXJzTW03VUVtcEduQktkV0lwdnE3bE9mdE1neFBQVDMyX2JDWnRqNS1IS3BMSFFSNFpJUnE2anV5anMwSkx1N1lrYkg1T0xNeFlIc2k1aFhKVEVSdFRpMExma0F5RjFpMWJ4V0pCSkNLWkNDd2dPbDhpNGQ3d1FleTFuVWRoZ0lRc1FXOXZJckhmU0l2QU94M2xlRmJUclFWUzdkOUpGTmZZWA?oc=5","date":"2025-09-12","type":"trial","source":"Fierce Biotech","summary":"Galimedix starts phase 2 fundraise after oral Alzheimer's candidate clears safety test - Fierce Biotech","headline":"Galimedix starts phase 2 fundraise after oral Alzheimer's candidate clears safety test","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-09-12","type":"trial","source":"GlobeNewswire","summary":"Progress in clinical development for Alzheimer’s and other indications: Galimedix Therapeutics successfully completes Phase 1 study with oral small molecule, GAL-101, an amyloid beta aggregation modul","headline":"Progress in clinical development for Alzheimer’s and other indications: Galimedix Therapeutics successfully completes Ph","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTFBPVVNHMkNSYWlHYlpOZ3JXdFc4cm9zSnhpS3BoSkJWY2tEVk1wZExsN1J5MldEVVI1ZzVuSGFQdFZGSFRiU3Q4UkpuczRUUDg3TklTM3MyTUpTNElIZ2pDM0wwR1ZxTE1HbXFSVUF5eWFBYVRSZFpKTWVGQ3RBRFk?oc=5","date":"2025-06-05","type":"pipeline","source":"Drug Discovery News","summary":"New AMD treatments: a race to prevent blindness and vision loss - Drug Discovery News","headline":"New AMD treatments: a race to prevent blindness and vision loss","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxPbkhyNmtObHZsNTN5bGx1dGY0aXE1ZWVqd1ZQWURBODFVVFMyS1lJMGRUcURKdVRqQTBhYnpCQ1BXSFMtcXFKSHhmR1hXSlZHaV8xUGlzd0YyaVFZY3J6VnZQUWIwOW40aFBWRjBJeUY4Q3NYTTBDb3JIYTVVNDdSSHE5T2xYYzJyQjBGMWNQMGNSRi1WY2pVcU9sTEhGaml3cmJtNW9zS0l3djZRYUwwWi1R?oc=5","date":"2025-05-09","type":"pipeline","source":"The Medicine Maker","summary":"A Small Molecule Drug Candidate for Alzheimer’s Treatment - The Medicine Maker","headline":"A Small Molecule Drug Candidate for Alzheimer’s Treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMia0FVX3lxTE1tRkI4SFFIbWNDaGRBMTE2TTRhamhBcmdjM29jY1hhbTliS1doOF9RVDJ2aWtqYmQ5YkF3YVpHZmpXZFFYZlRWUXJiTWt4T1p6UUVYdV9GUkR4SHloc0lVeW1QWnUyejJybmpJ?oc=5","date":"2025-05-07","type":"trial","source":"Clinical Trials Arena","summary":"Galimedix Therapeutics completes SAD portion of Phase I trial of oral GAL-101 - Clinical Trials Arena","headline":"Galimedix Therapeutics completes SAD portion of Phase I trial of oral GAL-101","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxPZXl5ZGtLU2ZpNnZwT2JFNHlVSUFxak45anRUcnhVYUdIWklnNldZZ3ZlYnFRRlF4QzJCVUZrckxNQkZPWlZOZnJ3bHlIMy14eWtYblhUV2NqOV9zVko4bTUzalctT21fa2xoTHJUa0hGcUdWcEVvUHJoaUtoM1lka1hOaG1VczdpbWc3djcyVXdjcGdlMWFPSWh2MlNwZ3ltcERzREdWbWRKRmNPU2UtdVpaSEhwRHQ4cmFLczR5Z1p4QWYyQ2MxVWVCZmFqQQ?oc=5","date":"2025-05-07","type":"trial","source":"Optometry Times","summary":"Galimedix Therapeutics completes single ascending dose portion of phase 1 trial assessing GAL-101 - Optometry Times","headline":"Galimedix Therapeutics completes single ascending dose portion of phase 1 trial assessing GAL-101","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxPTk50STJ6anpqZUEtckt6ZzlkU3lkRkxYajdwNUtTMFFxcTNyb0VHOC0yMThWQkRaZDV1TjRUbVFCTFpmd3NPaWs2UjRTMGgxTDlpVmxZTUJFZE0wYm5wMGpLYkZzeDhIUlBfQ3ZxSEJ5RWoyYjJuUERKVXJSVGxZQXd4enhzb05sdnZtd1g2bUR5N2hVVkhybUtnSnlUVEhpS3BB?oc=5","date":"2024-12-26","type":"trial","source":"Healio","summary":"Galimedix begins study of GAL-101 eye drops for dry AMD - Healio","headline":"Galimedix begins study of GAL-101 eye drops for dry AMD","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxOYnpMYjNHNnp3Y2F2bXNhOWwyRzFlYWpLM21Mbjc3elVtRVlib25aVHhGVVFlRlVCeEFKQ3BmbHVQV3RMMjhveVZzSGVIaUdvNHpSOWNiNzl4WHh3aWk2NjlrbFM2LTdrS0otd1NLbjFuM28yZkJyak05a2loX2l6SG1Xc19heUt3MlVLQkRHSWU5V20xTUdic28wVC1XOEpGQlBXUg?oc=5","date":"2024-12-06","type":"trial","source":"Ophthalmology Times","summary":"Galimedix Therapeutics initiates phase 1 trial of oral GAL-101 - Ophthalmology Times","headline":"Galimedix Therapeutics initiates phase 1 trial of oral GAL-101","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxNSkhuNFN2OVNpMjJHTk9MTzlGc0o0U3lISnJkRWZpTHB3QmRpTEpOdkNlQjFIZ1F6d1VrbHBmWkFPWmJRR3V2d3JQS2tRUUt2bjNBWXFwakg2dEg3V1BRTGZEQ3BJUGtkMHg0VmxoODVDMDFtOWlReXVhQk82MEppTjlHNmRoQkRMMjNDYmdCQjM3c0RVM05JNUs3Wmk5bXY2U2JIMTB4bkhmSUFBMkJ4SnlrSUFnTmRpMUZJbTY2QjF0U0tnalBKSkZ5dll3c29TUWd2NFdwd2o?oc=5","date":"2023-03-30","type":"pipeline","source":"Eyes On Eyecare","summary":"Théa Open Innovation, Galimedix collaborate for GAL-101 development and commercialization - Eyes On Eyecare","headline":"Théa Open Innovation, Galimedix collaborate for GAL-101 development and commercialization","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}